Genfit: elafibranor approved for PBC in the EU

(CercleFinance.com) - Genfit announces the conditional approval by the European Commission of Iqirvo (elafibranor) 80mg tablets for the treatment of Primary Biliary Cholangitis (PBC) in combination with ursodeoxycholic acid (AUDC) in adults.


As a reminder, the company developed elafibranor from its initial discovery to the end of the 52-week Phase III clinical trial, and licensed to Ipsen the exclusive worldwide rights (excluding China) to exploit the product, marketed under the brand name Iqirvo.

The expected payment of 26.5 million euros, upon pricing approval and reimbursement of Iqirvo in three European countries, will enable us to continue the development of our strong pipeline," says Genfit CEO Pascal Prigent.

Copyright (c) 2024 CercleFinance.com. All rights reserved.